Preterm birth complications are the leading cause of deaths among newborns and children younger than 5 years worldwide, contributing to an estimated 36% of neonatal mortality and 18% of under-5 deaths ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback